English   español  
Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/8801
Compartir / Impacto:
Estadísticas
Add this article to your Mendeley library MendeleyBASE
Citado 65 veces en Web of Knowledge®  |  Pub MebCentral Ver citas en PubMed Central  |  Ver citas en Google académico
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar otros formatos: Exportar EndNote (RIS)Exportar bibText (RIS)Exportar csv (RIS)
Título

Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1(BX08) gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B

AutorGómez, Carmen E.; Nájera García, José Luis; Pérez Jiménez, Eva; Jiménez, Victoria; Wagner, Ralf; Graf, Marcus; Frachette, Marie-Joelle; Liljeström, Peter; Pantaleo, Giuseppe; Esteban, Mariano
Palabras claveHIV/AIDS
Clade B vaccine
Poxvirus vectors
MVA
NYVAC
Immune response
Mouse models
Fecha de publicación16-oct-2006
EditorElsevier
CitaciónVaccine 25(15): 2863-2885 (2007)
ResumenIn this investigation we have generated and defined the immunogenicity of two novel HIV/AIDS vaccine candidates based on the highly attenuated vaccinia virus strains, MVA and NYVAC, efficiently expressing in the same locus (TK) and under the same viral promoter the codon optimized HIV-1 genes encoding gp120 and Gag-Pol-Nef antigens of clade B (referred as MVA-B and NYVAC-B). In infected human HeLa cells, gp120 is released from cells and GPN is produced as a polyprotein; NYVAC-B induces severe apoptosis but not MVA-B. The two poxvirus vectors showed genetic stability of the inserts. In BALB/c and in transgenic HHD mice for human HLA-A2 class I, both vectors are efficient immunogens and induced broad cellular immune responses against peptides represented in the four HIV-1 antigens. Some differences were observed in the magnitude and breadth of the immune response in the mouse models. In DNA prime/poxvirus boost protocols, the strongest immune response, as measured by fresh IFN-γ and IL-2 ELISPOT, was obtained in BALB/c mice boosted with NYVAC-B, while in HHD mice there were no differences between the poxvirus vectors. When the prime/boost was performed with homologous or with combination of poxvirus vectors, the protocols MVA-B/MVA-B and NYVAC-B/NYVAC-B, or the combination NYVAC-B/MVA-B gave the most consistent broader immune response in both mouse models, although the magnitude of the overall response was higher for the DNA-B/poxvirus-B regime. All of the immunization protocols induced some humoral response against the gp160 protein from HIV-1 clone LAV. Our findings indicate that MVA-B and NYVAC-B meet the criteria to be potentially useful vaccine candidates against HIV/AIDS.
Descripción23 pages, 8 figures.-- PMID: 17113200 [PubMed].-- Includes Appendix A: DNA sequence of MVA-B in the TK viral locus.-- Printed version published on Apr 12, 2007.
Versión del editorhttp://dx.doi.org/10.1016/j.vaccine.2006.09.090
URIhttp://hdl.handle.net/10261/8801
DOI10.1016/j.vaccine.2006.09.090
ISSN0264-410X
Aparece en las colecciones: (CNB) Artículos
Ficheros en este ítem:
No hay ficheros asociados a este ítem.
Mostrar el registro completo
 



NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.